This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahmadi, M. Articles by Morgan, D. J. Search for Related Content PubMed PubMed Citation Articles by Ahmadi, M. Articles by Morgan, D. J.

Prevention of Both Direct and Cross-Priming of Antitumor CD8⁺ T-Cell Responses following Overproduction of Prostaglandin E₂ by Tumor Cells In vivo

¹ Department of Cellular and Molecular Medicine, University of Bristol, School of Medical Sciences and ² Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Bristol, United Kingdom

Requests for reprints: David J. Morgan, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom. Phone: 44-117-3312021; Fax: 44-117-9287896; E-mail: d.j.morgan{at}bristol.ac.uk.

Key Words: CD8⁺ T-cell responses • tumor cells • COX-2 • PGE₂ • antigen presentation • cross-presentation • dendritic cells • peripheral tolerance

Defects in antitumor immune responses have been associated with increased release of prostaglandin E₂ (PGE₂) as a result of overexpression of cyclooxygenase (COX)-2 by tumors. In this report, we examine the effects of PGE₂ on antitumor CD8⁺ T-cell responses generated both by cross-presenting dendritic cells and by direct priming by tumor cells. Our data show that PGE₂ inhibits dendritic cell maturation, resulting in the abortive activation of naive CD8⁺ T cells, and is dependent on interleukin-10 production by dendritic cells. Interaction of tumor cells with naïve CD8⁺ T cells in the presence of PGE₂ in vitro results in the induction of CD8⁺ CD28^– T cells, which fail to proliferate or exhibit effector function. In vivo, overexpression of COX-2 by tumor cells results in a decrease in number of tumor-infiltrating dendritic cells and confers the ability of tumor cells to metastasize to the tumor draining lymph nodes. [Cancer Res 2008;68(18):7520–9]

This article has been cited by other articles:

				M. E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAGAVARAPU-CHARYULU, L. M. HERBERT, and D. M. LOPEZ Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors Anticancer Res, June 1, 2009; 29(6): 2051 - 2058. [Abstract] [Full Text] [PDF]

				A. Greenhough, H. J.M. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis, March 1, 2009; 30(3): 377 - 386. [Abstract] [Full Text] [PDF]